ArticleThe British journal of ophthalmology2001
Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion.
Article in The British journal of ophthalmology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Genetic correlation between Prothrombin G20210A polymorphism and retinal vein occlusion risk.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2019Pooled it
- Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: an updated meta-analysis.BMC ophthalmology · 2014Pooled it
- Relationship Between COVID-19 and Retinal Vein Occlusions.Journal of ophthalmology · 2025Review
- Review
- Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema.PloS one · 2022Article
- Role of von Willebrand factor in venous thromboembolic disease.JVS-vascular science · 2022Review
- Hyperhomocysteinemia, as an independent risk factor for retinal venous occlusion in an Indian population.Indian journal of clinical biochemistry : IJCB · 2013Article
- Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.International journal of ophthalmology · 2012Article
- Hyperhomocysteinemia and central retinal vein occlusion in Iranian population.International ophthalmology · 2008Article
- Branch retinal artery occlusion associated with compound heterozygous genotype for methylenetetrahydrofolate reductase.Documenta ophthalmologica. Advances in ophthalmology · 2007Article
- Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2006Article
- Plasma and aqueous humour levels of homocysteine in exfoliation syndrome.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo determine whether plasma homocysteine, methylene tetrahydrofolate reductase (MTHFR) C677T and factor II G20210A polymorphisms, factor VIII, and vWF are risk factors for central retinal vein occlusion (CRVO).
methodProspective comparison of 63 consecutive patients with central retinal vein occlusion and 63 age matched controls. Plasma homocysteine and vWF were estimated by ELISA, the MTFHR and factor II G20210A polymorphisms determined by polymerase chain reaction with restriction enzyme product digestion and factor VIII by one stage automated clotting assay.
resultsPlasma homocysteine (patients: median 12.4 micromol/l, controls: median 11.6 micromol OR = 1.05, p=0.20), factor VIII (patients: median = 115 U/dl, controls: median = 113 U/dl), and vWF (patients: median = 115 U/dl, controls: median = 108 U/dl) were not statistically higher in patients than in controls. Five CRVO patients and seven controls were homozygous for the MTHFR C677T mutation. One control was heterozygous for the factor II G20210A mutation.
conclusionThis study has not identified new risk factors for CRVO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.